Norges Bank acquired a new position in shares of Emergent Biosolutions Inc (NYSE:EBS) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 836,399 shares of the biopharmaceutical company’s stock, valued at approximately $49,581,000.

Several other institutional investors also recently bought and sold shares of EBS. Rehmann Capital Advisory Group increased its position in shares of Emergent Biosolutions by 78.7% during the fourth quarter. Rehmann Capital Advisory Group now owns 452 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 199 shares during the period. Quantamental Technologies LLC purchased a new position in Emergent Biosolutions in the fourth quarter valued at $29,000. Semmax Financial Advisors Inc. purchased a new position in Emergent Biosolutions in the fourth quarter valued at $30,000. Bronfman E.L. Rothschild L.P. increased its holdings in Emergent Biosolutions by 1,108.7% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 1,112 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 1,020 shares during the last quarter. Finally, Clarus Wealth Advisors increased its holdings in Emergent Biosolutions by 1,518.0% in the fourth quarter. Clarus Wealth Advisors now owns 1,618 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 1,518 shares during the last quarter. 84.63% of the stock is currently owned by institutional investors and hedge funds.

NYSE:EBS opened at $53.45 on Thursday. The firm has a market capitalization of $2.68 billion, a P/E ratio of 22.94, a price-to-earnings-growth ratio of 0.81 and a beta of 1.33. The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.07 and a current ratio of 3.10. Emergent Biosolutions Inc has a 12 month low of $46.93 and a 12 month high of $73.89.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Thursday, February 21st. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.14. Emergent Biosolutions had a net margin of 8.02% and a return on equity of 12.61%. The company had revenue of $270.70 million during the quarter, compared to the consensus estimate of $269.05 million. During the same quarter in the prior year, the firm posted $0.74 earnings per share. Emergent Biosolutions’s revenue for the quarter was up 39.7% on a year-over-year basis. Analysts predict that Emergent Biosolutions Inc will post 3.23 EPS for the current fiscal year.

In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 10,369 shares of the company’s stock in a transaction on Tuesday, February 26th. The shares were sold at an average price of $59.65, for a total value of $618,510.85. Following the completion of the transaction, the chairman now owns 1,478,306 shares in the company, valued at $88,180,952.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Adam Havey sold 3,043 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $58.11, for a total transaction of $176,828.73. Following the completion of the transaction, the executive vice president now owns 36,694 shares of the company’s stock, valued at approximately $2,132,288.34. The disclosure for this sale can be found here. Insiders sold 58,132 shares of company stock valued at $3,411,113 in the last 90 days. 13.40% of the stock is currently owned by insiders.

Several equities analysts recently commented on the company. Zacks Investment Research lowered Emergent Biosolutions from a “hold” rating to a “strong sell” rating in a report on Thursday, January 24th. ValuEngine raised Emergent Biosolutions from a “sell” rating to a “hold” rating in a report on Friday, March 29th. Wells Fargo & Co set a $68.00 target price on Emergent Biosolutions and gave the company a “hold” rating in a report on Tuesday, April 2nd. TheStreet lowered Emergent Biosolutions from a “b+” rating to a “c+” rating in a report on Tuesday, March 12th. Finally, Cantor Fitzgerald set a $75.00 target price on Emergent Biosolutions and gave the company a “buy” rating in a report on Thursday, December 13th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $70.43.

COPYRIGHT VIOLATION WARNING: This story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/norges-bank-takes-49-58-million-position-in-emergent-biosolutions-inc-ebs/2955318.html.

Emergent Biosolutions Profile

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Read More: Hedge Funds Explained

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.